Clinical Trial Update: A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor [Phase 2]

View source ↗

Summary

Phase 2 trial update on a single IV infusion of allogeneic MPCs in rheumatoid arthritis patients with incomplete response to TNF inhibitors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• MPCs

Snippet

Sponsor: Mesoblast, Ltd. | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED